» Articles » PMID: 36409990

Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman

Overview
Specialty Endocrinology
Date 2022 Nov 21
PMID 36409990
Authors
Affiliations
Soon will be listed here.
Abstract

Postmenopausal hyperandrogenism is a condition caused by relative or absolute androgen excess originating from the ovaries and/or the adrenal glands. Hirsutism, in other words, increased terminal hair growth in androgen-dependent areas of the body, is considered the most effective measure of hyperandrogenism in women. Other symptoms can be acne and androgenic alopecia or the development of virilization, including clitoromegaly. Postmenopausal hyperandrogenism may also be associated with metabolic disorders such as abdominal obesity, insulin resistance, and type 2 diabetes. Mild hyperandrogenic symptoms can be due to relative androgen excess associated with menopausal transition or polycystic ovary syndrome, which is likely the most common cause of postmenopausal hyperandrogenism. Virilizing symptoms, on the other hand, can be caused by ovarian hyperthecosis or an androgen-producing ovarian or adrenal tumor that could be malignant. Determination of serum testosterone, preferably by tandem mass spectrometry, is the first step in the endocrine evaluation, providing important information on the degree of androgen excess. Testosterone >5 nmol/L is associated with virilization and requires prompt investigation to rule out an androgen-producing tumor in the first instance. To localize the source of androgen excess, imaging techniques are used, such as transvaginal ultrasound or magnetic resonance imaging (MRI) for the ovaries and computed tomography and MRI for the adrenals. Bilateral oophorectomy or surgical removal of an adrenal tumor is the main curative treatment and will ultimately lead to a histopathological diagnosis. Mild to moderate symptoms of androgen excess are treated with antiandrogen therapy or specific endocrine therapy depending on diagnosis. This review summarizes the most relevant causes of hyperandrogenism in postmenopausal women and suggests principles for clinical investigation and treatment.

Citing Articles

Management of Common Benign Gynecologic Diseases in Postmenopausal Women.

Yu E, Lee H, Joo J, Na Y J Menopausal Med. 2025; 30(3):135-142.

PMID: 39829190 PMC: 11745728. DOI: 10.6118/jmm.24017.


Unusual Presentation of Hyperandrogenism in Postmenopausal Women: A Report of Two Patients With Leydig Cell Hyperplasia.

Duhamel F, Unuane D, Brock S, Cosyns S, Balti E Cureus. 2025; 16(12):e75640.

PMID: 39803098 PMC: 11725227. DOI: 10.7759/cureus.75640.


Molecular and Genetics Perspectives on Primary Adrenocortical Hyperfunction Disorders.

Kim S, Chaudhary P, Kim S Int J Mol Sci. 2024; 25(21).

PMID: 39518893 PMC: 11545009. DOI: 10.3390/ijms252111341.


Postmenopausal Hyperandrogenism Associated With Synchronous Ovarian Brenner Tumor, Bilateral Leydig Cell Tumor, and Adrenal Mass.

Salim M, Dasaraju S, Erickson B, Khalifa M, Burmeister L Cureus. 2024; 16(3):e55334.

PMID: 38559537 PMC: 10981901. DOI: 10.7759/cureus.55334.


Imaging features of intra-abdominal and intra-pelvic causes of hirsutism.

Li A, Bloomgarden N, Friedman S, Flusberg M, Chernyak V, Berkenblit R Abdom Radiol (NY). 2024; 49(6):2074-2082.

PMID: 38499827 PMC: 11213803. DOI: 10.1007/s00261-024-04189-9.


References
1.
Brown R, Joseph J, Cochran E, Gewert C, Semple R, Gorden P . Type B Insulin Resistance Masquerading as Ovarian Hyperthecosis. J Clin Endocrinol Metab. 2016; 102(6):1789-1791. PMC: 5470776. DOI: 10.1210/jc.2016-3674. View

2.
El-Maouche D, Arlt W, Merke D . Congenital adrenal hyperplasia. Lancet. 2017; 390(10108):2194-2210. DOI: 10.1016/S0140-6736(17)31431-9. View

3.
Della Corte L, Barra F, Mercorio A, Evangelisti G, Rapisarda A, Ferrero S . Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis. Expert Opin Drug Metab Toxicol. 2020; 16(9):759-768. DOI: 10.1080/17425255.2020.1789591. View

4.
Macut D, Ilic D, Mitrovic Jovanovic A, Bjekic-Macut J . Androgen-Secreting Ovarian Tumors. Front Horm Res. 2019; 53:100-107. DOI: 10.1159/000494906. View

5.
Tng E, Tan J . Dexamethasone suppression test versus selective ovarian and adrenal vein catheterization in identifying virilizing tumors in postmenopausal hyperandrogenism - a systematic review and meta-analysis. Gynecol Endocrinol. 2021; 37(7):600-608. DOI: 10.1080/09513590.2021.1897099. View